<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119496</url>
  </required_header>
  <id_info>
    <org_study_id>RES104033</org_study_id>
    <secondary_id>2004-004247-22 EUDRACT</secondary_id>
    <nct_id>NCT00119496</nct_id>
  </id_info>
  <brief_title>Rosiglitazone Versus Theophylline in Asthmatic Smokers</brief_title>
  <official_title>A Clinical Study to Investigate the Effect of Rosiglitazone, Theophylline and Inhaled Corticosteroid, Inflammation and Pulmonary Function in Asthmatic Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chest, Heart and Stroke Association Scotland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chief Scientist Office of the Scottish Government</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Glasgow</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthmatic smokers display a blunted response to both inhaled and oral corticosteroid
      treatments and are at increased risk for exacerbations and near fatal asthma. The prevalence
      of smoking in asthmatics runs between 20-30%. Therefore, new, more efficacious treatments are
      required.

      Recent work has demonstrated a mechanism which may explain steroid resistance. A commonly
      used drug called theophylline can reverse this steroid resistance in laboratory studies.
      Another commonly used drug, rosiglitazone can reverse smoking induced lung inflammation in
      laboratory studies.

      The investigators aim to study the effects of these drugs on smoking asthmatics' lung
      function and other parameters including quality of life and asthma control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smoking asthmatics have chronic pulmonary inflammation that is relatively steroid resistant.
      PPAR agonists (of which rosiglitazone is one example) have been shown to reduce several
      markers of inflammation in humans and in smoking animal models.

      This clinical study will use smoking asthmatics as a human model of smoke-induced
      steroid-insensitive airway inflammation to evaluate both efficacy of rosiglitazone as an
      anti-inflammatory drug as well as the effect of low doses of theophylline on the response to
      low-dose inhaled corticosteroid (LD ICS).

      Mild or moderate (as per GINA guidelines) persistent-asthmatic smokers will be randomised
      into this study after a 4-week washout period during which they will be withdrawn from
      inhaled corticosteroids (ICS). Subjects will then receive one of four treatments for 28 days:
      rosiglitazone, LD ICS, theophylline, or LD ICS plus theophylline.

      The effects of rosiglitazone and LD ICS on pulmonary function will be compared as a primary
      objective. In addition, effects of theophylline plus LD ICS will be compared against
      theophylline and LD ICS separately. Both pulmonary anti-inflammatory and systemic
      anti-inflammatory activity will also be investigated.

      Subjects will have baseline assessments of pulmonary function, biomarkers of systemic
      inflammation, sputum, exhaled breath biomarkers, asthma control questionnaires and safety
      parameters. Following 28 days of treatment, these parameters will all be reassessed in all
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of pre-bronchodilator (FEV1) at 28 days between rosiglitazone and LD ICS treatment groups.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rosiglitazone vs LD ICS on other endpoints of pulmonary function in smoking asthmatics.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Theophylline plus LD ICS vs LD ICS on pulmonary function in smoking asthmatics.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Theophylline plus LD ICS vs theophylline on pulmonary function in smoking asthmatics.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of rosiglitazone, LD ICS, theophylline and theophylline plus LD ICS in smoking asthmatics.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects in smoking asthmatics of rosiglitazone, LD ICS, theophylline and theophylline plus LD ICS on asthma control using the ACQ (Juniper et al, 1999).</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled beclomethasone (400mcg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosiglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral theophylline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral theophylline and inhaled beclomethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
    <description>oral tablet, 4mg bd for 4 weeks</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Rosiglitazone Maleate, Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>theophylline</intervention_name>
    <description>Oral theophylline, 200mg bd</description>
    <arm_group_label>Arm3</arm_group_label>
    <other_name>uniphyllin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beclomethasone</intervention_name>
    <description>inhaled beclomethasone, 200mcg bd</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Qvar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled beclomethasone and oral theophylline</intervention_name>
    <description>inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)</description>
    <arm_group_label>Arm 4</arm_group_label>
    <other_name>Qvar and uniphyllin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females between 18 and 60 years of age (inclusive).

          -  Clinical diagnosis of mild or moderate persistent asthma in accordance with the Global
             Initiative for Asthma (GINA) criteria

          -  Have had a history of asthma for a minimum of 6 months prior to entry into the study

          -  Subjects must be current cigarette smokers with a minimum five-pack-year smoking
             history

          -  Baseline FEV1 that is greater than 50% predicted; and reversibility of 12% or more at
             screening, washout or randomisation.

          -  Capable of providing signed written informed consent and complying with all the
             specified study procedures.

        Exclusion Criteria:

          -  Asthma exacerbation or a respiratory tract infection within four weeks of screening.

          -  Type 1 or type 2 diabetes mellitus.

          -  Women who are lactating, pregnant, or planning to become pregnant.

          -  Clinically significant renal or hepatic laboratory values (e.g. AST/ALT/total
             bilirubin/AP &gt; 2.5 times normal values).

          -  Anaemia (&lt; 11 g/dL for males or &lt; 10 g/dL for females)

          -  Contraindications to treatment as outlined in any of the product labels

          -  Prior history of severe oedema or serious fluid related event (e.g., heart failure)
             associated with any TZD

          -  The subject has a history of significant hypersensitivity to study drugs

          -  Presence of unstable or severe angina or congestive heart failure (NYHA class III/IV)
             or evidence or history of known congestive heart failure (NYHA class I-IV) or an
             abnormal electrocardiogram (ECG), as determined by the Investigator, or subjects who
             have had new cardiac events (such as MI, new CHF, PTCA, CABG) within 6 months of
             screening.

          -  History or suspicion of current drug abuse or alcohol abuse within the last 6 months.

          -  History suggestive of active infection or non-asthma lung pathology

          -  Clinically significant renal disease, metabolic syndrome, cirrhosis (Child-Pugh Class
             B/C), hypertension or any other clinically significant cardiovascular, neurological,
             endocrine, or haematological abnormalities that are uncontrolled on permitted therapy.

          -  Risk factors for human immunodeficiency virus (HIV), hepatitis B or hepatitis C
             infection at Screening (Visit 1)

          -  Subjects who are morbidly obese, defined as having a body mass index (BMI) &gt; 40 kg/m2

          -  Unable to perform spirometry

          -  Subjects who require treatment with any of the following asthma medications from
             Screening (Visit 1) until study completion:

               -  Inhaled cromolyn sodium or nedocromil;

               -  Ipratropium bromide;

               -  Xanthines (theophylline preparations);

               -  Leukotriene modifiers;

               -  Long-acting inhaled beta2-agonists (salmeterol, formoterol);

               -  Oral beta2-agonists.

          -  Treatment with oral, intravenous or intra-articular corticosteroids within 6 weeks of
             Screening or thereafter.

          -  Subjects who have been taking in excess of 1000 Î¼g daily of beclomethasone (or
             equivalent) within 6 weeks of Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil C Thomson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma Research Group, Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.gla.ac.uk/departments/immunology/respiratorymedicine/</url>
    <description>Asthma Research Unit website</description>
  </link>
  <reference>
    <citation>Spears M, McSharry C, Thomson NC. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy. 2006 Dec;36(12):1494-504. Review.</citation>
    <PMID>17177672</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2005</study_first_submitted>
  <study_first_submitted_qc>July 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <last_update_submitted>January 26, 2010</last_update_submitted>
  <last_update_submitted_qc>January 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2010</last_update_posted>
  <keyword>Corticosteroid</keyword>
  <keyword>Rosiglitazone</keyword>
  <keyword>Theophylline</keyword>
  <keyword>Beclomethasone</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Asthma</keyword>
  <keyword>Smoking</keyword>
  <keyword>Pulmonary</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

